Vaccine mix, Ema: “It may be a strategy to be adopted, but limited data”

“The” coronavirus first and second dose “vaccine mix approach has been successfully adopted in the past and it is well known that mixing vaccines often results in a better immune response. But” about Covid vaccines “we have evidence limited, even if some preliminary studies have shown that the immune response appears to be satisfactory and no particular safety problems are emerging. So it could be a strategy to adopt but certainly the evidence is limited and it is important that we collect more information and we monitor carefully “. This was stated by Marco Cavaleri, head of Vaccines and Therapeutic Products for Covid-19 of the European Medicines Agency Ema, today during the periodic press briefing. “From Ema’s point of view it is not easy at the moment to come up with a clinical recommendation also because it is not clear if” companies that have authorized vaccines “are interested in submitting any requests for changes in product information,” he added.